
Lambert-Eaton Myasthenic Syndrome (LEMS): Shaping Patient Journeys Through Eye Care (Online CME Monograph)
Activity Description and Purpose
This continuing medical education activity provides ophthalmologists with a comprehensive overview of Lambert-Eaton myasthenic syndrome (LEMS), a rare immune-mediated disorder affecting the neuromuscular junction that can present with ocular symptoms, such as ptosis and diplopia. Ophthalmologists play a crucial role in the early detection and referral of LEMS. Through expert faculty discussion and a detailed case study, ophthalmologists will learn to recognize potential patients with LEMS, understand appropriate diagnostic measures, such as voltage-gated calcium channel antibody testing and repetitive nerve stimulation, and evaluate clinical trial data on treatment options, including the US Food and Drug Administration–approved therapy amifampridine. The desired results of this activity are for ophthalmologists to improve their ability to implement timely referrals, identify appropriate diagnostic measures, and evaluate clinical trial data on treatment for LEMS.
Watch a patient with LEMS share her journey from diagnosis to treatment and current outlook at courses.mededicus.com/LEMSInterview
Target Audience
This educational activity is intended for ophthalmologists.
Learning Objectives
After completing this activity, participants will be better able to:
- Implement referrals on the basis of clinical features of Lambert-Eaton myasthenic syndrome
- Identify the appropriate diagnostic measures for Lambert-Eaton myasthenic syndrome
- Evaluate clinical trial data on treatment for Lambert-Eaton myasthenic syndrome
Faculty
![]() | Fiona Costello, MD, FRCPC (Co-Chair) Professor of Neurology Departments of Clinical Neurosciences and Surgery Cumming School of Medicine University of Calgary Clinician Scientist Hotchkiss Brain Institute Calgary, Canada |
![]() | Michael Lee, MD (Co-Chair) Professor Departments of Ophthalmology, Neurology, and Neurosurgery Mackall-Scheie Endowed Chair Director of Neuro-Ophthalmology University of Minnesota Minneapolis, Minnesota |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Fiona Costello, MD, is an advisory board member of Amgen Inc*; and is on the speakers bureau for Sanofi*.
Michael Lee, MD, is a consultant for Eli Lilly and Company and Panbela Therapeutics, Inc; is an advisory board member of Amgen Inc*, is a contracted researcher for Invex Therapeutics*, and has stocks or stock options in Viridian Therapeutics, Inc*.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, manager, and writers have no relevant commercial relationships to disclose.
* The financial relationship existed during the past 24 months but has now ended
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Catalyst Pharmaceuticals, Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at [email protected].
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Catalyst Pharmaceuticals, Inc, or the American Academy of Ophthalmology.
This CME activity is copyrighted to MedEdicus LLC ©2025. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 330.2
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation